APN-1808

Key Takeaways: Results from a simple, finger prick blood test are promising and may help detect Alzheimer's at home or in the doctor's office. A blood test was more than 80% accurate in identifying Alzheimer's-related changes — significantly better than doctors in the study who did not have access to the test. Blood tests for Alzheimer's could improve diagnostic accuracy and treatment of the disease. AMSTERDAM, July 19, 2023 /PRNewswire/ -- A simple, finger prick blood test — not so different from what people with diabetes do every day — shows promise in the ability to detect Alzheimer's disease, according to research reported for the first time today at the Alzheimer's Association International Conference® (AAIC®) 2023, in Amsterdam, Netherlands, and online. Advancements in technology and practice reported for the first time at AAIC 2023 demonstrate the simplicity, transportability and diagnostic value of blood-based biomarkers for Alzheimer's, including the future potential for at-home testing by a patient or a family member. "These findings are timely and important with the recent U.S. Food and Drug Administration approvals of Alzheimer's treatments targeting amyloid-beta where confirmation of amyloid buildup and biomarker monitoring are required to receive treatment," said Maria C. Carrillo, Ph.D., Alzheimer's Association chief science officer. "Blood tests — once verified and approved — would offer a quick, noninvasive and cost-effective option." Blood tests are already being implemented in Alzheimer's drug trials for further verification of their effectiveness and for screening potential participants, which would be a significant evolution from more expensive and invasive procedures that are currently common practice. In some cases, these blood tests are providing similar information to "gold standard" testing, such as brain imaging scans and cerebrospinal fluid analysis. "While further standardization and validation are needed, blood tests may soon be an important piece of the diagnostic workup in everyday practice for detecting and monitoring treatment of Alzheimer's disease," Carrillo said. Finger Prick Blood Sample Detects Alzheimer's Biomarkers; Travels Easily Between Countries Hanna Huber, Ph.D., of the Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Sweden, and colleagues set out to simplify and increase the accessibility of blood tests by developing a finger prick blood collection to measure key Alzheimer's-related biomarkers neurofilament light (NfL), glial fibrillary acidic protein (GFAP) and phosphorylated tau (p-tau181 and 217). They collected blood (from both vein and finger prick) from 77 memory clinic patients from the ACE Alzheimer Center, Barcelona. The blood samples were transferred onto dry blood spot cards and shipped overnight, without temperature control or cooling, to the University of Gothenburg, Sweden. There, the dried blood samples were extracted from the cards, and NfL, GFAP and p-tau181 and 217 were measured. (Note: p-tau217 data is only available in 11 people.) All were detectable in the finger prick samples. In the vein blood spots, the levels of GFAP, NfL, p-tau217 and p-tau181 associated strongly with standard blood analysis. GFAP, NfL and p-tau217 extracted from finger prick blood also correlated highly with standard blood collection. "Our pilot study demonstrates the potential of remote collection and measurement of Alzheimer's biomarkers without low-temperature storage or extraordinary preparation or processing," Huber said. "Currently, use of Alzheimer's blood tests is limited by the need to visit a clinic, administration by trained personnel, and strict time-limited and temperature-dependent delivery and storage procedures. A method that allows blood collection at home and that is simple enough to be performed independently, or by caregivers, would increase accessibility of these tests. It would result in improved early diagnosis and better monitoring of patients considered 'at risk' or those who are receiving approved therapies." Blood Tests May Improve Alzheimer's Diagnosis in Primary Care Sebastian Palmqvist, M.D., Ph.D., of the Clinical Memory Research Unit at Lund University, Sweden, and colleagues with the BioFINDER-Primary Care study conducted the first study to examine the use of blood-based biomarkers for Alzheimer's in primary care and compare them to the diagnostic accuracy of primary care physicians (PCPs). The study recruited 307 middle-aged to elderly patients at 17 primary care centers in Sweden (mean age=76, 48% women). After an office visit, cognitive testing and a CT scan or MRI of the brain, the PCPs registered their diagnosis, the likely biological cause(s) and proposed a treatment plan for each study participant. At the same time, a blood sample was collected and analyzed to determine the concentrations of beta-amyloid and phosphorylated tau using the PrecivityAD2 test by C2N Diagnostics (USA). Levels of these two markers were combined into a score called the Amyloid Probability Score 2 (APS2). All patients then underwent a thorough clinical examination at a specialized memory clinic, including evaluation by a specialist blinded to the blood sample result. The PCPs correctly identified the presence of Alzheimer's-related changes or correctly diagnosed Alzheimer's in approximately 55% of the cases, while the blood test did so in more than 85% of the cases. Other findings: The PCPs indicated their certainty about the diagnosis was less than 50%. The treatment plans revealed that, due to incorrect diagnosis, more than 50% of people who actually had Alzheimer's did not receive symptomatic treatment, and 30% of non-Alzheimer's cases incorrectly received symptomatic treatment. "Due to the lack of accurate diagnostic tools, it is currently very difficult for primary care doctors to identify Alzheimer's disease, even among patients with cognitive impairment," Palmqvist said. "This too often leads to diagnostic uncertainty and inappropriate treatment. Blood tests for Alzheimer's disease have great potential for improving diagnostic accuracy and proper treatment of people with Alzheimer's. These tests may become even more important in the near future, as new drugs that slow down the disease in its early stages become more widely available." About the Alzheimer's Association International Conference® (AAIC®) The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias. As a part of the Alzheimer's Association's research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community. AAIC 2023 home page: AAIC 2023 newsroom: AAIC 2023 hashtag: #AAIC23 About the Alzheimer's Association® The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900. Hanna Huber, Ph.D., et al. A finger prick collection method for detecting blood biomarkers of neurodegeneration – a pilot study (DROP-AD). (Funder: Alzheimerfonden) Sebastian Palmqvist, M.D., Ph.D., et al. Blood Biomarkers Improve The Diagnostic Accuracy Of Alzheimer's Disease As Compared With Current Diagnostic Standard In the Primary Care Setting. (Funders: Alzheimer's Association, Swedish Research Council, Swedish Brain Foundation, Swedish Alzheimer's Foundation) SOURCE Alzheimer's Association

The biomarker blood test will play an important role in the evaluation of patients experiencing cognitive symptoms consistent with early signs of Alzheimer’s Disease (AD) and help determine appropriate treatment planning for suspected patient Quanterix rolls out LucentAD biomarker blood test. (Credit: Milad Fakurian on Unsplash) Quanterix has launched LucentAD, a biomarker blood test to support the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer’s disease (AD). The LucentAD test will help clinicians, in conjunction with other diagnostic tools, to rapidly determine the likelihood of a patient having amyloid pathology that indicates AD. Also, the information provided by the test will help healthcare providers determine appropriate follow-up and treatment planning for a suspected Alzheimer’s patient. Currently, the LucentAD test is run by the health technology company’s CLIA laboratory, which also conducts several clinical trials related to AD. Quanterix has launched Lucent Diagnostics, a new healthcare provider-facing portal that addresses the needs of patients, along with a therapy for the disease. Quanterix CEO Masoud Toloue said: “A year ago, Quanterix announced the validation of our laboratory-developed test to quantitatively measure p-Tau 181 in plasma as an aid in diagnostic evaluation of Alzheimer’s disease. “The launch of Lucent Diagnostics and availability of the LucentAD test expands access to our p-Tau 181 test for healthcare providers and marks an important step in our goal to help build a global Alzheimer’s disease testing infrastructure.” “Non-invasive blood biomarker testing is the only way to democratize access to Alzheimer’s disease therapies and Quanterix will offer our testing solutions to healthcare providers who want to provide this important service to patients.” The test measures an isoform of phosphorylated tau protein in plasma, which is phosphorylated at the 181 residues of the protein (p-Tau 181). The concentration of tau protein in plasma and cerebrospinal fluid has been positively correlated to the presence of amyloid pathology in the brain, a hallmark of Alzheimer’s disease. LucentAD leverages the Simoa p-Tau 181 assay, which has been extensively studied in large longitudinal and cross-sectional cohorts, with established specificity for AD pathology. Quanterix said that Lucent Diagnostics will announce additional tests aimed at improving the diagnosis and management of Alzheimer’s and other neurological disorders.